Skip to main content

Traveler's Diarrhea

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Dr. Falk Pharma
Dr. Falk PharmaGermany - Freiburg
1 program
1
Rifamycin SV-MMX®Phase 31 trial
Active Trials
NCT01208922Completed835Est. May 2016
RedHill Biopharma
RedHill BiopharmaIsrael - Tel Aviv
2 programs
2
Rifamycin SV MMXPhase 21 trial
Rifamycin SV-MMXPhase 21 trial
Active Trials
NCT04027894Unknown142Est. Dec 2025
NCT04026984Unknown142Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dr. Falk PharmaRifamycin SV-MMX®
RedHill BiopharmaRifamycin SV-MMX
RedHill BiopharmaRifamycin SV MMX

Clinical Trials (3)

Total enrollment: 1,119 patients across 3 trials

NCT01208922Dr. Falk PharmaRifamycin SV-MMX®

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

Start: Nov 2010Est. completion: May 2016835 patients
Phase 3Completed
NCT04026984RedHill BiopharmaRifamycin SV-MMX

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Start: Jun 2024Est. completion: Dec 2025142 patients
Phase 2Unknown
NCT04027894RedHill BiopharmaRifamycin SV MMX

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Start: Jan 2024Est. completion: Dec 2025142 patients
Phase 2Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.